Management of tuberculosis in HIV-infected patients

AIDS Reviews

Volumn 14, Issue 4, 2012, Pages 231-246

  Curran, Adrian ^a   Falcó, Vicenç ^a   Pahissa, Albert ^a   Ribera, Esteban ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiretroviral therapy; Drug drug interaction; HIV; IRIS; Tuberculosis

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; AZD 5847; BEDAQUILINE; COBICISTAT; DELAMANID; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETHAMBUTOL; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NELFINAVIR; NEVIRAPINE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RILPIVIRINE; SAQUINAVIR; STAVUDINE; STREPTOMYCIN; SUTEZOLID; TENOFOVIR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; EXTRAPULMONARY TUBERCULOSIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; MIXED INFECTION; MORTALITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TUBERCULOSIS; TUBERCULOUS MENINGITIS; UVEITIS; VIRUS HEPATITIS; VIRUS LOAD;

ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUBERCULOSIS;

EID: 84871644483     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Global tuberculosis control 2011. Available at: http://www.who.int/tb/ publications/global-report/en.
2. Kirk O, Gatell J, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group. Am J Respir Crit Care Med. 2000;162:865-72.
3. Girardi E, Sabin C, d'Arminio Monforte A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005;4:1772-82. (Pubitemid 41759864)
4. Lawn S, Bekker L, Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5:361-73. (Pubitemid 40779257)
5. Valin N, Pacanowski J, Denoeud L, et al. Risk factors for 'unmasking immune reconstitution inflammatory syndrome' presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients. AIDS. 2010;24:1519-25.
6. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr. 2009;50:148-52.
7. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect. 2006;52:188-94. (Pubitemid 43286185)
8. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:42-6. (Pubitemid 44306486)
9. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One. 2009;4:e5575.
10. Abdool Karim S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.
11. Abdool Karim S, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492-501.
12. Blanc F, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-81.
13. Havlir D, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-91.
14. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results from the TIME Study. J Acquir Immune Defic Syndr. 2012;60:377-83.
15. Torok M, Yen N, Chau T, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV) - associated tuberculous meningitis. Clin Infect Dis.2011;52:1374-83.
16. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-61.
17. Lawn S, Bekker L, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS. 2005;19:2050-2. (Pubitemid 41669038)
18. Yew W. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002;25:111-33. (Pubitemid 34261186)
19. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated 2011. Available at http://www.aidsinfo.nih.gov/ guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/.
20. GeSIDA. Documento de consenso de Gesida/ Secretaría del Plan Nacional sobre el Sida sobre el tratamiento antirretroviral del adulto Actualización enero 2012. Available at: http://www.gesida-seimc.org/ pcientifica/fuentes/DcyRc/gesidadcyrc2011-Documentoconsenso-TAR-adulto- verordenador.pdf.
21. Pozniak A, Coyne K, Miller R, et al. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med. 2011;12:517-24.
22. Treatment of tuberculosis guidelines. Fourth Edition 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf.
23. Rifabutin prescribing information. Food and Drug Administration. Update May 2008. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2008/050689s016lbl.pdf.
24. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49:1305-11.
25. Jenny-Avital E, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009;48:1471-4.
26. Loeliger A, Suthar A, Ripin D, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis. 2012;16:6-15.
27. Sterling T, Villarino M, Borisov A, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-66.
28. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353:1843-7. (Pubitemid 29251017)
29. Coyne K, Pozniak A, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS. 2009;23:437-46.
30. Aguado J, Torre-Cisneros J, Fortun J, et al. Consensus document for the management of tuberculosis in solid organ transplant recipients. Enferm infecc Microbiol Clin. 2009;27:465-73.
31. Burman W. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin Infect Dis. 2010;50(Suppl 3):S165-72.
32. Diacon A, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397-405.
33. Dooley K, Park J, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012;59:455-62.
34. van Heeswijk R, Meyvisch P, DeMarez T, et al. The effect of nevirapine on the pharmacokinetics of TMC207, an investigational antimycobacterial agent, in HIV-1-infected subjects. 6th IAS Conference on HIV Pathogenesis, Prevention, and Treatment, July 2011. Rome, Italy. [Abstract MOPE172].
35. van Heeswijk R, Meyvisch P, De Marez T, et al. The effect of lopinavir/ritonavir on the pharmacokinetics of TMC207, an investigational antimycobacterial agent. 18th International AIDS Conference, July 2010. Vienna, Austria. [Abstract WEPE0089].
36. Diacon A, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010;54:3402-7.
37. Jia L, Tomaszewski J, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol. 2005;144:80-7. (Pubitemid 40192564)
38. Wallis R, Jakubiec W, Kumar V, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother. 2011;55:567-74.
39. van Hest R, Baars H, Kik S, et al. Hepatotoxicity of rifampin- pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39:488-96. (Pubitemid 39120923)
40. Gordin F, Cohn D, Matts J, Chaisson R, O'Brien R. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis. 2004;39:561-5. (Pubitemid 39120935)
41. Ribera E, Azuaje C, Lopez R, et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother. 2007;59:690-7. (Pubitemid 47073403)
42. Ribera E, Azuaje C, Lopez R, et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). J Acquir Immune Defic Syndr. 2005;40:317-23. (Pubitemid 41533072)
43. Schmitt C, Riek M, Winters K, Schutz M, Grange S. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf. 2009;2:8-16.
44. Haas D, Koletar S, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009;50:290-3.
45. Sustiva Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd. Update 2011. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR---Product-Information/human/000249/WC500058311.pdf
46. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58:1299-302. (Pubitemid 44884158)
47. Lopez-Cortes L, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681-90.
48. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20:131-2. (Pubitemid 41818129)
49. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005;19:1481-6. (Pubitemid 41400693)
50. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother. 2009;53:4545-8.
51. Orrell C, Cohen K, Conradie F, et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011;16:527-34.
52. Lopez-Cortes L, Ruiz-Valderas R, Ruiz-Morales J, et al. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother. 2006;58:1017-23.
53. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and comedication. Antivir Ther. 2008;13:675-85.
54. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS. 2005;19:1541-3. (Pubitemid 41400701)
55. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infec Dis. 2009;48:1752-9.
56. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53:716-24.
57. Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007;44:141-4. (Pubitemid 44969000)
58. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006;43:253-5.
59. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61:389-93.
60. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28:450-3. (Pubitemid 34033196)
61. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr. 2006;42:36-41. (Pubitemid 43947944)
62. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13:529-36. (Pubitemid 352016715)
63. Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson U. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol. 2009;65:71-80.
64. Shipton L, Wester C, Stock S, et al. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis. 2009;13:360-6.
65. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530-9.
66. Deeks E, Keating G. Etravirine. Drugs. 2008;68:2357-72.
67. Kakuda T, Scholler-Gyure M, Hoetelmans R. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50:25-39.
68. Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl). 2011;3:35-44.
69. Avihingsanon A, van der Lugt J, Singphore U, et al. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A Pilot Study. AIDS Res Hum Retroviruses. 2012;28:1170-6.
70. Kashuba A. Drug-drug interactions and the pharmacotherapy of HIV infection. Top HIV Med. 2005;13:64-9.
71. Polk R, Brophy D, Israel D, et al. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother. 2001;45:502-8. (Pubitemid 32105287)
72. Rolla V, da Silva Vieira M, Pereira Pinto D, et al. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig. 2006;26:469-79.
73. Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med. 2007;8:131-4. (Pubitemid 46390850)
74. Acosta E, Kendall M, Gerber J, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother. 2007;51:3104-10. (Pubitemid 350067515)
75. Burger D, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3336-42. (Pubitemid 44527507)
76. la Porte CJ Colbers E, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:1553-60.
77. Nijland H, L'Homme R, Rongen G, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008;22:931-5. (Pubitemid 351652243)
78. Decloedt E, McIlleron H, Smith P, Merry C, Orrell C, Maartens G. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother. 2011;55:3195-200.
79. Curran A, Ribera E. HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin. Expert Rev Anti Infect Ther. 2011;9:1115-18.
80. Decloedt E, Maartens G, Smith P, Merry C, Bango F, McIlleron H. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PloS One. 2012;7:e32173.
81. Colby D, Quang V, Vinh Chau V, et al. Safety and tolerability of super-boosted ritonavir administered with lopinavir and rifampin for HIV/TB co-infection in a developing county. 19th CROI, 2012. Seattle, USA. [Abstract 930].
82. Wenning L, Hanley W, Brainard D, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852-6.
83. Burger D, Magis-Escurra C, van den Berk G, Gelinck L. Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS. 2010;24:328-30.
84. Raltegravir Summary of Product Characteristics, MSD Pharmaceuticals Ltd. Updated July 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000860/WC500037405.pdf
85. Weiner M, Engle M, et al. The pharmacokinetic interaction between raltegravir and rifapentine in healthy volunteers. 19th CROI, 2012. Seattle, USA. [Abstract 615].
86. Ramanathan S, Mathias A, German P, Kearney B. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50:229-44.
87. Ramanathan S, Stondell T, Cheng A, Kearney B. Pharmacokinetics and drug interaction profile of cobicistat boosted-EVG with atazanavir, rosuvastatin or rifabutin. 13th International Workshop on Clinical Pharmacology of HIV Therapy, 2012. Barcelona, Spain. [Abstract O-03].
88. Dooley K, Purdy E, Sayre P, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin: Results of a phase I study among healthy subjects. 19th CROI, 2012. Seattle, USA. [Abstract 148].
89. Dooley K, Sayre P, Borland J, et al. Pharmacokinetics, safety, and tolerability of the HIV integrase inhibitor dolutegravir co-administered with rifabutin in healthy subjects. 13th International Workshop on Clinical Pharmacology of HIV Therapy, 2012. Barcelona, Spain. [Abstract P-11].
90. Abel S, Jenkins T, Whitlock L, Ridgway C, Muirhead G. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl 1):38-46. (Pubitemid 351366537)
91. Celsentri Summary of Product Characteristics, Pfizer Pharmaceuticals Ltd, Updated June 2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000811/WC500022190.pdf
92. Fuzeon Prescribing Information. 2012. Accessed at: http://www.gene.com/ gene/products/information/fuzeon/pdf/pi.pdf.
93. Gulick R, Ribaudo H, Shikuma C, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-61. (Pubitemid 38917251)